Early Psychosis (Path Program)
On this page
Get care
The UCSF Path Program for Early Psychosis is a clinic focused on timely recognition and treatment of psychosis. We work with teens and young adults (age 35 or younger) who are experiencing symptoms that indicate they are at risk for the condition. Our goal is to help patients and their families get the help and resources they need as early as possible to prevent symptoms from worsening.
Psychosis is not a specific illness but a term that describes a range of mental health symptoms. These may include changes in thoughts and perceptions that can make people feel confused or distressed when interacting with the world. The symptoms can come and go and may vary in intensity over time, but sometimes they persist and worsen, disrupting day-to-day activities, such as studying, working or socializing.
Our team of psychiatrists and therapists helps patients understand what they're experiencing and navigate uncertainties. Our goal is to support their recovery and journey to full re-engagement in life. When a patient enters the program, we carry out a diagnostic assessment and develop an individualized wellness plan. We offer individual and group therapy; medication management; and skill building to help with practical challenges, such as returning to school or applying for a job. We also offer support and education for families. Because we focus on the early stages of psychosis – when treatment is most effective – our participants typically graduate from our program in about two years.
At the Path Program, we are also committed to research on the risk factors and initial warning signs of psychosis. Our ongoing clinical trials (studies) are open to eligible individuals regardless of health insurance status.
Learn more about clinical trials and how they work.
The UCSF Path Program for Early Psychosis is a clinic focused on timely recognition and treatment of psychosis. We work with teens and young adults (age 35 or younger) who are experiencing symptoms that indicate they are at risk for the condition. Our goal is to help patients and their families get the help and resources they need as early as possible to prevent symptoms from worsening.
Psychosis is not a specific illness but a term that describes a range of mental health symptoms. These may include changes in thoughts and perceptions that can make people feel confused or distressed when interacting with the world. The symptoms can come and go and may vary in intensity over time, but sometimes they persist and worsen, disrupting day-to-day activities, such as studying, working or socializing.
Our team of psychiatrists and therapists helps patients understand what they're experiencing and navigate uncertainties. Our goal is to support their recovery and journey to full re-engagement in life. When a patient enters the program, we carry out a diagnostic assessment and develop an individualized wellness plan. We offer individual and group therapy; medication management; and skill building to help with practical challenges, such as returning to school or applying for a job. We also offer support and education for families. Because we focus on the early stages of psychosis – when treatment is most effective – our participants typically graduate from our program in about two years.
At the Path Program, we are also committed to research on the risk factors and initial warning signs of psychosis. Our ongoing clinical trials (studies) are open to eligible individuals regardless of health insurance status.
Learn more about clinical trials and how they work.
Get care
Providers
Devanand Manoli, MD, PhD
Pediatric Psychiatry
Daniel Mathalon, MD, PhD
Psychiatry
Demian Rose, MD
Psychiatry
Vikaas S. Sohal, MD, PhD
Psychiatry
Awards & recognition
Rated high-performing hospital for psychiatry care
Related conditions & treatments
Treatments
- Psychotherapy
- Psychological Testing and Evaluation
- Clinical Trials
Our research initiatives
Path ProgramOpens in a new window
The Path Program conducts research on early psychosis and the clinical high-risk syndrome, often with collaborators across the U.S. and around the world, in order to advance our understanding of the causes of psychosis and to test innovative treatments.